Tempus AI, Inc. (NASDAQ:TEM) Director Wayne A.I. Frederick Sells 3,000 Shares

Tempus AI, Inc. (NASDAQ:TEM) Director Wayne A.I. Frederick sold 3,000 shares of the stock in a transaction on Monday, March 31st. The stock was sold at an average price of $45.54, for a total value of $136,620.00. Following the sale, the director now owns 26,514 shares in the company, valued at $1,207,447.56. The trade was a 10.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Tempus AI Stock Up 5.7 %

Shares of Tempus AI stock traded up $2.67 during trading on Wednesday, reaching $49.89. The company’s stock had a trading volume of 8,405,862 shares, compared to its average volume of 5,283,473. The firm’s 50-day moving average is $58.64 and its two-hundred day moving average is $51.56. Tempus AI, Inc. has a 52-week low of $22.89 and a 52-week high of $91.45. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

Analysts Set New Price Targets

TEM has been the topic of several recent research reports. Needham & Company LLC raised their price target on Tempus AI from $56.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday, February 25th. TD Cowen reaffirmed a “buy” rating and issued a $74.00 target price (up from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. JPMorgan Chase & Co. downgraded shares of Tempus AI from an “overweight” rating to a “neutral” rating and lifted their price objective for the company from $50.00 to $55.00 in a report on Tuesday, February 25th. Piper Sandler lowered their price target on Tempus AI from $70.00 to $55.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Finally, Bank of America upped their target price on shares of Tempus AI from $54.00 to $60.00 and gave the company a “neutral” rating in a report on Monday, March 3rd. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $61.18.

Hedge Funds Weigh In On Tempus AI

A number of institutional investors have recently bought and sold shares of the stock. ARK Investment Management LLC increased its holdings in shares of Tempus AI by 132.1% in the 4th quarter. ARK Investment Management LLC now owns 5,519,644 shares of the company’s stock worth $186,343,000 after purchasing an additional 3,141,487 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Tempus AI by 166.0% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,239,093 shares of the company’s stock valued at $109,352,000 after buying an additional 2,021,394 shares in the last quarter. Nikko Asset Management Americas Inc. lifted its position in shares of Tempus AI by 166.0% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 3,239,093 shares of the company’s stock valued at $109,352,000 after buying an additional 2,021,394 shares in the last quarter. Franklin Resources Inc. grew its stake in shares of Tempus AI by 240.5% during the 4th quarter. Franklin Resources Inc. now owns 2,762,173 shares of the company’s stock valued at $93,251,000 after acquiring an additional 1,950,862 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in Tempus AI by 86,947.2% during the fourth quarter. JPMorgan Chase & Co. now owns 1,653,896 shares of the company’s stock valued at $55,836,000 after acquiring an additional 1,651,996 shares during the period. 24.22% of the stock is owned by institutional investors.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.